Follow The Filings

ADCT ADC Therapeutics

ADC Therapeutics earnings company data as of 8:10 AM ET 11/16

  • 2 of 2 EPS beats

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS -0.21 -0.06 Beat
Rev $19.1M $21.7M Beat +13.9%
FY2026 Q2 13 Aug EPS -0.22 -0.11 Beat
Rev — — —

Insider trades

Open-market buys and sales by ADCT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ADCT insider trades
  • None no insider bought on the open market
  • $19.6M sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Redmile Group, LLC 10% owner, +2 joint filers
    Sale
    $19.6M 5,880,415 shares at $3.34
    Traded Mar 31–Apr 2 Filed Apr 2

Also filed in the last 12 months, not counted as buying or selling: 17 share withholdings for taxes and 16 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
424B3 FORM 424B3
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
8-K 2.02,7.01,8.01,9.01
SCHEDULE 13G —
8-K 1.01,2.02,3.02,9.01
SCHEDULE 13G —
8-K 2.02,7.01,9.01
10-Q
SCHEDULE 13G —
8-K 5.02
8-K 7.01,8.01,9.01
8-K 7.01,8.01,9.01
8-K 5.07,9.01
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
DEF 14A
DEFA14A FORM DEFA14A
424B3 FORM 424B3
SCHEDULE 13G/A —
424B3 FORM 424B3
8-K 2.02,9.01
10-K

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf